Outlook Therapeutics falls after starting equity offering
12/08/2026 21:21
BUZZ-Outlook Therapeutics falls after starting equity offering ** Shares of Outlook Therapeutics OTLK.O down ~13% post-market as it looks to raise equity
** New Jersey-based biopharma commences offering of stock and accompanying warrants; deal size not disclosed
** Co intends to use net offering proceeds to support commercialization of its eye-disease drug, Lytenava, in the U.S., and for working capital and other purposes
** Piper Sandler and BTIG joint bookrunners
** On Jul 24, U.S. FDA approved the drug to treat wet age-related macular degeneration (AMD)
** OTLK closed down 2.7% at $1.10 on Weds, down 30% YTD
** Co has ~187 mln shares outstanding
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))